$FBIO
Fortress Biotech, Inc. Stock $fbio

$fbio Overview Financials Valuation SEC Filings Company Website

2016 Q3 Form 10-Q Financial Statement

#000114420416117796 Filed on August 09, 2016

Income Statement

Concept	2016 Q3	2016 Q2	2015 Q2
Revenue	$975.0K	$2.230M	$0.00
YoY Change	3800.0%
Cost Of Revenue	$41.00K	$324.0K	$0.00
YoY Change
Gross Profit	$934.0K	$1.906M	$0.00
YoY Change	3636.0%
Gross Profit Margin	95.79%	85.47%
Selling, General & Admin	$8.864M	$8.635M	$4.530M
YoY Change	9.72%	90.62%	89.54%
% of Gross Profit	949.04%	453.04%
Research & Development	$7.316M	$2.060M	$2.411M
YoY Change	-19.37%	-14.56%	1.43%
% of Gross Profit	783.3%	108.08%
Depreciation & Amortization	$200.0K	$82.00K	$5.000K
YoY Change	3233.33%	1540.0%	-16.67%
% of Gross Profit	21.41%	4.3%
Operating Expenses	$17.22M	$17.37M	$7.762M
YoY Change	-4.84%	123.73%	62.96%
Operating Profit	-$17.18M	-$17.04M	-$7.762M
YoY Change	-5.07%	119.56%	62.96%
Interest Expense	$689.0K	$529.0K	$352.0K
YoY Change	96.86%	50.28%	195.8%
% of Operating Profit
Other Income/Expense, Net	-$710.0K	-$1.253M	$1.344M
YoY Change	-60.18%	-193.23%	2484.62%
Pretax Income	-$16.96M	-$16.39M	-$6.420M
YoY Change	-14.6%	155.3%	36.31%
Income Tax
% Of Pretax Income
Net Earnings	-$12.98M	-$12.48M	-$6.175M
YoY Change	-28.52%	102.07%	31.08%
Net Earnings / Revenue	-1331.38%	-559.55%
Basic Earnings Per Share
Diluted Earnings Per Share	-$323.4K	-$313.0K	-$158.0K
COMMON SHARES
Basic Shares Outstanding	48.67M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q3	2016 Q2	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$84.70M	$71.30M	$66.60M
YoY Change	21.68%	7.05%	-12.48%
Cash & Equivalents	$82.54M	$71.34M	$41.04M
Short-Term Investments	$2.200M		$25.57M
Other Short-Term Assets	$5.600M	$1.600M	$1.000M
YoY Change	409.09%	60.0%	150.0%
Inventory	$123.0K	$100.0K
Prepaid Expenses
Receivables	$5.007M	$967.0K
Other Receivables	$3.200M	$2.500M
Total Short-Term Assets	$98.60M	$76.60M	$62.03M
YoY Change	48.05%	23.48%	-18.91%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.164M	$4.500M	$90.00K
YoY Change	1064.0%	4900.0%	-10.0%
Goodwill	$21.74M
YoY Change
Intangibles
YoY Change
Long-Term Investments	$250.0K	$250.0K	$250.0K
YoY Change	0.0%	0.0%	-16.67%
Other Assets	$48.00K	$14.60M	$172.0K
YoY Change	-99.68%	8388.37%	-98.78%
Total Long-Term Assets	$46.82M	$21.46M	$21.67M
YoY Change	131.06%	-0.94%	50.45%
TOTAL ASSETS
Total Short-Term Assets	$98.60M	$76.60M	$62.03M
Total Long-Term Assets	$46.82M	$21.46M	$21.67M
Total Assets	$145.4M	$98.06M	$83.70M
YoY Change	67.41%	17.16%	-7.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$21.80M	$5.100M	$583.0K
YoY Change	1593.86%	774.79%	94.33%
Accrued Expenses	$8.605M	$8.500M	$4.386M
YoY Change	20.57%	93.8%	41.48%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$38.59M	$14.30M	$4.995M
YoY Change	356.72%	186.29%	45.33%
LONG-TERM LIABILITIES
Long-Term Debt	$27.40M	$21.80M	$23.20M
YoY Change	17.6%	-6.03%	65.71%
Other Long-Term Liabilities	$4.583M	$3.700M	$264.0K
YoY Change	2168.81%	1301.52%	-64.99%
Total Long-Term Liabilities	$4.583M	$25.50M	$264.0K
YoY Change	2168.81%	9559.09%	-75.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$38.59M	$14.30M	$4.995M
Total Long-Term Liabilities	$4.583M	$25.50M	$264.0K
Total Liabilities	$70.58M	$62.70M	$28.49M
YoY Change	120.96%	120.07%	53.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$227.8M		-$160.0M
YoY Change	27.9%		19.89%
Common Stock	$49.00K		$47.00K
YoY Change	4.26%		6.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$36.63M	$35.34M	$55.88M
YoY Change
Total Liabilities & Shareholders Equity	$145.4M	$98.10M	$83.70M
YoY Change	67.41%	17.21%	-7.92%

Cashflow Statement

Concept	2016 Q3	2016 Q2	2015 Q2
OPERATING ACTIVITIES
Net Income	-$12.98M	-$12.48M	-$6.175M
YoY Change	-28.52%	102.07%	31.08%
Depreciation, Depletion And Amortization	$200.0K	$82.00K	$5.000K
YoY Change	3233.33%	1540.0%	-16.67%
Cash From Operating Activities	-$8.820M	-$7.380M	-$6.160M
YoY Change	-41.86%	19.81%	53.23%
INVESTING ACTIVITIES
Capital Expenditures	-$1.460M	-$2.160M	-$50.00K
YoY Change	3550.0%	4220.0%
Acquisitions
YoY Change
Other Investing Activities	$3.620M	-$2.060M	-$1.700M
YoY Change	-131.95%	21.18%	466.67%
Cash From Investing Activities	$2.160M	-$4.220M	-$1.750M
YoY Change	-119.0%	141.14%	483.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	17.86M	1.520M	30.00K
YoY Change	61.34%	4966.67%	-76.92%
NET CHANGE
Cash From Operating Activities	-8.820M	-7.380M	-6.160M
Cash From Investing Activities	2.160M	-4.220M	-1.750M
Cash From Financing Activities	17.86M	1.520M	30.00K
Net Change In Cash	11.20M	-10.08M	-7.880M
YoY Change	-172.4%	27.92%	88.07%
FREE CASH FLOW
Cash From Operating Activities	-$8.820M	-$7.380M	-$6.160M
Capital Expenditures	-$1.460M	-$2.160M	-$50.00K
Free Cash Flow	-$7.360M	-$5.220M	-$6.110M
YoY Change	-51.35%	-14.57%	51.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	14586000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	14586000	USD
CY2016Q2	us-gaap	Long Term Investments LongTermInvestments	766000	USD
CY2015Q4	us-gaap	Long Term Investments LongTermInvestments	2485000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1579000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1250000	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	35337000	USD
CY2016Q2	us-gaap	Minority Interest MinorityInterest	22877000	USD
CY2016Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	58214000	USD
CY2016Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	302000	USD
CY2015Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	114000	USD
CY2016Q2	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	2570000	USD
CY2015Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	156000	USD
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	14600000	USD
CY2016Q2	us-gaap	Notes Payable NotesPayable	14000000	USD
	fbio	Percentage Of Tax Benefit Likely Of Being Realized PercentageOfTaxBenefitLikelyOfBeingRealized	0.5	pure
CY2016Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4677000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	377000	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	142000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	68000	USD
CY2016Q2	us-gaap	Depreciation Depreciation	82000	USD
CY2015Q2	us-gaap	Depreciation Depreciation	5000	USD
	us-gaap	Depreciation Depreciation	86000	USD
	us-gaap	Depreciation Depreciation	11000	USD
CY2014Q1	us-gaap	Equity Method Investments EquityMethodInvestments	250000	USD
CY2014Q1	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.35	pure
CY2016Q2	us-gaap	Equity Method Investments EquityMethodInvestments	250000	USD
	fbio	Percentage Of Outstanding Stock To Be Issued Upon Exercise Of Warrants PercentageOfOutstandingStockToBeIssuedUponExerciseOfWarrants	0.25	pure
CY2016Q2	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	766000	USD
CY2015Q4	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	2485000	USD
CY2016Q2	us-gaap	Long Term Debt LongTermDebt	22217000	USD
CY2015Q4	us-gaap	Long Term Debt LongTermDebt	24009000	USD
CY2016Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	412000	USD
CY2015Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	835000	USD
CY2016Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	2800000	USD
	us-gaap	Interest Expense InterestExpense	1149000	USD
	us-gaap	Interest Expense InterestExpense	683000	USD
CY2016Q2	us-gaap	Interest Expense InterestExpense	529000	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	352000	USD
CY2016Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1566000	USD
CY2015Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2492000	USD
CY2016Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	650000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	382000	USD
CY2016Q2	fbio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	1018000	USD
CY2015Q4	fbio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	810000	USD
CY2016Q2	fbio	Other Short Term Liabilities Related To Manufacturing Rights OtherShortTermLiabilitiesRelatedToManufacturingRights	1987000	USD
CY2015Q4	fbio	Other Short Term Liabilities Related To Manufacturing Rights OtherShortTermLiabilitiesRelatedToManufacturingRights	1500000	USD
CY2016Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	431000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	523000	USD
CY2016Q2	fbio	Accrued Expenses Releted To Dr Falk Pharma Milestone AccruedExpensesReletedToDrFalkPharmaMilestone	2776000	USD
CY2015Q4	fbio	Accrued Expenses Releted To Dr Falk Pharma Milestone AccruedExpensesReletedToDrFalkPharmaMilestone	2717000	USD
	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	31226000	USD
CY2015	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	32882000	USD
CY2015	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5455000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12348653	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10489695	shares
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	5889000	USD
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3395000	USD
CY2016Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3023000	USD
CY2015Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1925000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1779365	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1754365	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1065501	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.37
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	666396	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	597262	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.41
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.77
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y3M25D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y9M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y4M2D
	fbio	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue	0	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	573662	USD
CY2016Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	33000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P11D
CY2016Q2	fbio	Employee Stock Purchase Plan Offering Fair Value Reckoning Percentage EmployeeStockPurchasePlanOfferingFairValueReckoningPercentage	0.85	pure
CY2015Q2	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	8000	USD
CY2015Q2	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	44000	USD
CY2016Q3	us-gaap	Prepaid Rent PrepaidRent	199000	USD
	fbio	Lease Sharing Agreements Contributions To Property Under Lease LeaseSharingAgreementsContributionsToPropertyUnderLease	4500000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	Fortress Biotech, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001429260
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	FBIO
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48668630	shares
CY2016Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	967000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2016Q2	us-gaap	Inventory Net InventoryNet	100000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2016Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	1000000	USD
CY2015Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Use of Estimates</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	981000	USD
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1364000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48668630	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48668630	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47147032	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47147032	shares
CY2016Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	324000	USD
CY2015Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	324000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
	us-gaap	Investments In And Advances To Affiliates At Fair Value Period Increase Decrease InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease	1700000	USD
CY2016Q2	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	500000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	74000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11000	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	167000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	423000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	84000	USD
	us-gaap	Cost Of Goods Sold Amortization CostOfGoodsSoldAmortization	21000	USD
	us-gaap	Cost Of Goods Sold Amortization CostOfGoodsSoldAmortization	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5889000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3395000	USD
	fbio	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	-48000	USD
	fbio	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	0	USD
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	249000	USD
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	0	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	2095000	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	8629000	USD
	us-gaap	Trading Securities Unrealized Holding Gain Loss TradingSecuritiesUnrealizedHoldingGainLoss	0	USD
	us-gaap	Trading Securities Unrealized Holding Gain Loss TradingSecuritiesUnrealizedHoldingGainLoss	-2000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	100000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	967000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	2414000	USD
	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	42000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-195000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	253000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3571000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	920000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-1000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-2000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	3122000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-624000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-19019000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8073000	USD
	fbio	Payment For Research And Development Licenses PaymentForResearchAndDevelopmentLicenses	2095000	USD
	fbio	Payment For Research And Development Licenses PaymentForResearchAndDevelopmentLicenses	8629000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4300000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	49000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	350000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1250000	USD
	us-gaap	Payments For Proceeds From Mortgage Deposits PaymentsForProceedsFromMortgageDeposits	1000	USD
	us-gaap	Payments For Proceeds From Mortgage Deposits PaymentsForProceedsFromMortgageDeposits	0	USD
	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	175000	USD
	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	108000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6921000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-10036000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	216000	USD
	fbio	Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan	81000	USD
	fbio	Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan	26000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	570000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	49000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2792000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	0	USD
	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	10000000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	855000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1000000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	150000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-906000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	9387000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-26846000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8722000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49759000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41037000	USD
	us-gaap	Interest Paid InterestPaid	158000	USD
	us-gaap	Interest Paid InterestPaid	80000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1000	USD
CY2016Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1998000	USD
CY2015Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	727000	USD
CY2015Q2	us-gaap	Assets Assets	83699000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3884000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1300000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	1099000	USD
CY2015Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	2599000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-1719000	USD
CY2016Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	2068000	USD
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	4160000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	1407000	USD
CY2015Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	5567000	USD
CY2016Q2	fbio	Accrued Cost Of Good Sold AccruedCostOfGoodSold	309000	USD
CY2015Q4	fbio	Accrued Cost Of Good Sold AccruedCostOfGoodSold	0	USD
CY2016Q2	fbio	Lease Impairment Current LeaseImpairmentCurrent	146000	USD
CY2015Q4	fbio	Lease Impairment Current LeaseImpairmentCurrent	146000	USD
CY2016Q2	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	3706000	USD
CY2015Q4	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	584000	USD
	us-gaap	Sale Of Stock Percentage Of Ownership After Transaction SaleOfStockPercentageOfOwnershipAfterTransaction	0.12	pure
CY2016Q2	fbio	Reimbursement Of Transaction Expenses ReimbursementOfTransactionExpenses	800000	USD
CY2016Q2	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	21000	USD
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	84000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.10
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	25000	shares
	fbio	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue	0	USD
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	88000	USD
	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	16000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	81000	USD
	fbio	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	434000	USD
	fbio	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	0	USD
CY2015Q1	fbio	Agreement Description Terms AgreementDescriptionTerms	(i) issue annually to the Company, on the anniversary date of the Founders Agreement, shares of common stock equal to 2.5% of the fully-diluted outstanding equity of Checkpoint at the time of issuance; (ii) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Checkpoint or any of its subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when the Company no longer has majority voting control in Checkpoints voting equity, equal to 2.5% of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to 4.5% of Checkpoints annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Founders Agreement), Checkpoint will pay a one-time change in control fee equal to five times (5x) the product of (i) net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).
CY2016Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	10000	shares
CY2016Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	150556	shares
CY2016Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	49000	USD
CY2016Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	400000	USD
CY2016Q2	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	30000	USD
	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	56000	USD
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	33958	shares
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	2230000	USD
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	2890000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	500000	USD
CY2016Q2	us-gaap	Gross Profit GrossProfit	1906000	USD
CY2015Q2	us-gaap	Gross Profit GrossProfit	0	USD
	us-gaap	Gross Profit GrossProfit	2566000	USD
	us-gaap	Gross Profit GrossProfit	500000	USD
CY2015Q1	fbio	Agreement Description Terms AgreementDescriptionTerms	(i) issue annually to the Company, on the anniversary date of the Founders Agreement, shares of common stock equal to two and one half percent (2.5%) of the fully-diluted outstanding equity of Avenue at the time of issuance; (ii) pay an equity fee in shares of Avenue common stock, payable within five (5) business days of the closing of any equity or debt financing for Avenue or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when Fortress no longer has majority voting control in Avenues voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to four and one half percent (4.5%) of Avenues annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Founders Agreement), the Company will pay a one-time change in control fee equal to five (5x) times the product of (i) monthly net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).
CY2015Q1	fbio	Agreement Description Terms AgreementDescriptionTerms	(i) issue annually to the Company, on the anniversary date of the Founders Agreement, shares of common stock equal to two and one half percent (2.5%) of the fully-diluted outstanding equity of Helocyte at the time of issuance; (ii) pay an equity fee in shares of Helocyte common stock, payable within five (5) business days of the closing of any equity or debt financing for Helocyte or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when Fortress no longer has majority voting control in Helocytes voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to four and one half percent (4.5%) of Helocytes annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Founders Agreement), the Company will pay a one-time change in control fee equal to five (5x) times the product of (i) monthly net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).
CY2015Q1	fbio	Agreement Description Terms AgreementDescriptionTerms	(i) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Mustang or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when the Company no longer has majority voting control in Mustangs voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of Mustangs annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control, Mustang will pay a one-time change in control fee equal to five (5x) times the product of (A) monthly net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%).
	us-gaap	Stock Issued1 StockIssued1	48000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	99000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD

Files In Submission

Name	View Source	Status
0001144204-16-117796-index-headers.html	Edgar Link	pending
0001144204-16-117796-index.html	Edgar Link	pending
0001144204-16-117796.txt	Edgar Link	pending
0001144204-16-117796-xbrl.zip	Edgar Link	pending
fbio-20160630.xml	Edgar Link	completed
fbio-20160630.xsd	Edgar Link	pending
fbio-20160630_cal.xml	Edgar Link	unprocessable
fbio-20160630_def.xml	Edgar Link	unprocessable
fbio-20160630_lab.xml	Edgar Link	unprocessable
fbio-20160630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v445521_10q.htm	Edgar Link	pending
v445521_ex31-1.htm	Edgar Link	pending
v445521_ex31-2.htm	Edgar Link	pending
v445521_ex32-1.htm	Edgar Link	pending
v445521_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBIO
Fortress Biotech, Inc. Stock $fbio

2016 Q3 Form 10-Q Financial Statement

#000114420416117796 Filed on August 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO Fortress Biotech, Inc. Stock $fbio

2016 Q3 Form 10-Q Financial Statement

#000114420416117796 Filed on August 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO
Fortress Biotech, Inc. Stock $fbio